Special Issue

Tumors of the Central Nervous System

Submission Deadline: October 15, 2018 (Closed)

Guest Editor

Antonio Meola, M.D. Ph.D

Clinical Assistant Professor of Neurosurgery, Department of Neurosurgery, Stanford University School of Medicine, 300 Pasteur Drive, Edwards Bldg. 94304, Stanford, CA

Website | E-Mail

Research Interests: Brain Tumors, Skull Base Surgery, Image-guided Neurosurgery, Radiosurgery

About This Topic

The WHO classification of Tumors of the Central Nervous System (CNS) highlighted the pivotal role of molecular and genetic markers for predicting tumor biological behavior, therapy response and patient prognosis. We seek original research articles focusing on genetic, molecular and radiological features of CNS tumors that might impact on clinical practice, including clinical and preclinical data. Additionally, we invite submission of reviews, editorials, case reports, technical reports elucidating biological features of the CNS tumors, the interaction of tumors with healthy nervous tissue, as well as illustrating the effect of medications and cutting-edge technology on CNS tumor diagnosis and treatment.

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (neurobiology@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!

Publication

Open Access Editorial Editorial: “A New Era in Neuro-Oncology” by Antonio Meola Received: 05 May 2019;  Published: 08 May 2019;  doi: 10.21926/obm.neurobiol.1902025

Open Access Review Diffuse Intrinsic Pontine Glioma: Translation of Genomic Knowledge to Clinical Practice by Tina Zhou  , Sara Khan  , Ron Firestein  , Peter Downie  and Jason E Cain Received: 29 November 2018;  Published: 12 March 2019;  doi: 10.21926/obm.neurobiol.1901022 Abstract Pediatric brain tumors account for approximately 25% of all cancers in children and are currently the leading cause of cancer-related deaths in the pediatric population with an estimated incidence of 5.14 cases per 100,000 persons [1]. Up to 10-15% of all pediatric brain tumors arise in the brainstem, with the majority of these classified [...]

Open Access Review Sporadic and Hereditary Hemangioblastoma: The Role of Endothelial Cells by Alberto Feletti  , Elena Bianchini  , Anna De Gaetano  , Lara Gibellini  , Sara De Biasi  , Giacomo Pavesi  , Anna Vittoria Mattioli  , Milena Nasi  , Andrea Cossarizza  and Marcello Pinti Received: 26 November 2018;  Published: 04 March 2019;  doi: 10.21926/obm.neurobiol.1901021 Abstract Hemangioblastomas (HBs) are benign, highly vascularized tumors of the central nervous system. About 75% of HBs are sporadic, while 25% are associated with von Hippel-Lindau (VHL) disease. HBs consist of two main components, a rich capillary network composed of vascular endothelia and pericytes, within large vacuolated stromal cells, which [...]

Open Access Research Article Magnetic Resonance Imaging Approaches for Predicting the Response to Hyperoxic Radiotherapy in Glioma-Bearing Rats by Pilar López-Larrubia  , Nuria Arias-Ramos  and Jesús Pacheco-Torres Received: 11 November 2018;  Published: 30 January 2019;  doi: 10.21926/obm.neurobiol.1901020 Abstract Background: Despite the advances in multimodal therapeutic options, glioblastoma (GBM), the most frequent and aggressive of all astrocytomas, remains with a median survival of 15 months. It is reported a direct correlation between GBM hypoxia and a higher aggressiveness, poor prognosis and greater resistance to different treatments. Because [...]

Open Access Research Article Correlation of CT and MR Perfusion and Permeability Parameters for Intracranial Tumors by Kirsten Greenlaw  and Jai Jai Shiva Shankar Received: 07 October 2018;  Published: 13 January 2019;  doi: 10.21926/obm.neurobiol.1901019 Abstract Background and Purpose: Perfusion imaging, mainly MR perfusion (MRP), is performed frequently for brain tumor imaging. CT perfusion (CTP) is less studied as a method for characterizing brain tumors. The purpose of this study was to demonstrate the usefulness of CTP perfusion parameters in evaluating brain tumors and to compare it with MRP [...]

Open Access Case Report Cerebellopontine Angle Glioblastoma with Concurrent Spinal Cord Involvement: A Case Report and Review of Literature by Rahul Abhyankar  , Divya B. Mella  and Edward Pan Received: 12 November 2018;  Published: 04 January 2019;  doi: 10.21926/obm.neurobiol.1901018 Abstract Objective: To report a unique case of cerebellopontine angle glioblastoma with concurrent spinal cord involvement. Background: Glioblastoma (GBM) is the most common primary malignancy of the central nervous system (CNS), comprising 46.6% of all CNS malignancies. By anatomic location, cerebellopontine angle (CPA) GBMs are exceedingly rare [...]

Open Access Review Sleep Disorders in Children with Central Nervous System Tumors by Melissa A. Maloney  , Katherine E. Lewinter  , Sally L. Davidson Ward  and Iris A. Perez Received: 13 November 2018;  Published: 16 December 2018;  doi: 10.21926/obm.neurobiol.1804017 Abstract Sleep complaints are common in pediatric patients with central nervous system (CNS) tumors. These problems may result from disruption of normal homeostatic, circadian, neuroendocrine, and cardiorespiratory pathways and vary by tumor location and treatment received. Children with tumors within the hypothalamus and surrounding regions are prone [...]

Open Access Original Research TTF-1-Expressing Supratentorial Embryonal Tumors (PNET): A Clinicopathologic Study of Two Cases and Literature Review of TTF-1-Positive Primary Brain Tumors by Michele Bisceglia  , Stefano Pizzolitto  , Tullio Parracino  , Giovanna De Maglio  , Elena Minenna  , Serena D’Agostini  and Carlos A. Galliani Received: 07 October 2018;  Published: 14 November 2018;  doi: 10.21926/obm.neurobiol.1804016 Abstract Thyroid transcription factor 1 (TTF-1) is a nuclear polypeptide, tissue-restricted member of the homeobox protein family, that when attached to DNA plays a crucial role in regulating the expression of select genes during early embryonic development of the thyroid, lung, and brain. As often happens, the initial enthusiasm for the diagnostic [...]

Open Access Review Angiocentric Glioma: A Review of Clinicopathologic Features by Richard A. Prayson Received: 04 September 2018;  Published: 05 November 2018;  doi: 10.21926/obm.neurobiol.1804015 Abstract Along with focal cortical dysplasia, hippocampal sclerosis and remote infarcts, tumors are a well known cause of medically intractable or pharmacoresistent epilepsy [1-3]. Most of the tumors encountered in this setting represent low grade glioneuronal neoplasms, particularly gangliogliomas and dysembryoplastic neuroepithelial tumors. In [...]

Open Access Case Report A Case Series of Temozolomide in the Management of Refractory Prolactinomas by Divya B. Mella  , Josie Sewell  and Edward Pan Received: 12 October 2018;  Published: 01 November 2018;  doi: 10.21926/obm.neurobiol.1804014 Abstract Objective: To report three cases of refractory prolactinomas treated with Temozolomide (TMZ). Background: Prolactinomas account for 40% of pituitary adenomas. Dopamine agonists (DA) are the first line of treatment followed by surgical resection and radiation. TMZ is an oral chemotherapeutic agent used in gliomas, which has been given to patien [...]

Open Access Research Article Isolated Diffusion Restriction Preceding Contrast Enhancement in Glioblastoma Multiforme is Associated with Short-Term Survival by Jai Jai Shiva Shankar  , Adil Bata  and Namita Sinha Received: 07 August 2018;  Published: 25 October 2018;  doi: 10.21926/obm.neurobiol.1804013 Abstract Background: Current imaging standard for detecting and assessing glioblastoma multiforme (GBM) progression depends on contrast-enhancement on brain magnetic resonance imaging (MRI). Isolated foci of diffusion restriction have been observed to precede enhancement in GBM. The aim of our study was to investigate the frequency of isolated diffusio [...]

Open Access Review Craniopharyngiomas: An Appropriate Surgical Treatment based on Topographical and Pathological Concepts by Ruth Prieto  and Jose M Pascual Received: 11 September 2018;  Published: 15 October 2018;  doi: 10.21926/obm.neurobiol.1804012 Abstract Treatment of craniopharyngiomas (CPs) represents a neurosurgical challenge, the major reason being their close relationship with the hypothalamus and the third ventricle (3V) boundaries. Nevertheless, CPs are generally defined as “suprasellar” lesions, an imprecise and frequently faulty term. Despite being heterogeneous lesions, CPs are [...]

Open Access Review Contribution of PET Imaging to Clinical Management of Gliomas by Wolf-Dieter Heiss Received: 02 July 2018;  Published: 19 September 2018;  doi: 10.21926/obm.neurobiol.1803011 Abstract Gliomas originating from glial cells, comprise about 30 % of all primary central nervous system tumors and 80 % of malignant brain tumors. Gliomas are different with respect to their biological activity and are categorized according to grades, from benign to malignant with high recurrence rates. For diagnosis location and extent of tumor is [...]